Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic adipose-derived mesenchymal stromal cells to reduce primary graft dysfunction after lung transplantation
2019-004848-30Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary graft dysfunction (PGD), bronchopulmonary dysplasia (BPD) and airway morbidity comparing CSCC_ASC arm with Placebo arm (2 arms). Primary endpoint: Primary graft dysfunction incidence and grade at 72 hours. Started Dec 2019; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
primary graft dysfunction (PGD)bronchopulmonary dysplasia (BPD)airway morbidity
Beyond the preview
Go deeper on 2019-004848-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004848-30.